Lung Cancer.pdf

Table 9–5. (continued) Third-Generation Platinum-Containing Doublets versus Second-Generation Platinum-Containing Doublets
Median 1-Year Side Effects
Study and No. of Response Survival Survival P for Quality of Worse Than with
Treatment Regimen Patients Rate Time Rate Survival Life Other Regimen
Crino (1999)
Cisplatin mitomycin/
ifosfamide 152 26% 9.6 months 34% Alopecia
Cisplatin gemcitabine 155 38% (P .029) 8.6 months 33% .877 Same Thrombocytopenia
Martoni (1998) NR
Cisplatin epirubicin 95 33% 10.5 months Myelosuppression,
alopecia
Cisplatin vinorelbine 103 27% 9.6 months
Takiguchi (2000) NR
Cisplatin vindesine 101 22% 11.5 months 48% Neutropenia
Cisplatin irinotecan 98 29% 10.4 months 43% .760 Diarrhea
Belani (1998) NR
Cisplatin etoposide 179 14% 9.1 months 37% Vomiting, myalgias
Carboplatin paclitaxel 190 22% (P .059) 7.7 months 32% NR Neurotoxicity
Danson (2001)
Carboplatin gemcitabine 145 31% 7.3 months .273 Hematologic
Cisplatin mitomycin C 151 34% 8.5 months
ifosfamide OR cisplatin
mitomycin C vinblastine
* For cisplatin and etoposide versus cisplatin and paclitaxel 135 mg/m 2 .
† For cisplatin and etoposide versus cisplatin and paclitaxel 135 mg/m 2 .
‡ When both paclitaxel arms combined compared with etoposide arm.
P not reported for response or survival. Data from Schiller et al, 2000.
Treatment of Patients with Advanced Non–Small Cell Lung Cancer 171